ArticleMolecular cancer2026
CircKIAA1617 promotes stemness via USP14/PGRMC1-mediated autophagy and lipid metabolism reprogramming in ER-positive breast cancer.
Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is the most common neoplasm in women, and its growth mainly depends on estrogen, but the mechanism of estrogen in BC is still not fully understood. Circular RNAs (circRNAs) represent a novel type of regulatory RNA characterized by high evolutionary conservation and stability. This study aimed to investigate the roles and mechanisms of circRNAs in ER-positive BC.
methodsCircKIAA1617 was identified through high-throughput RNA sequencing in ER-positive BC. Gain- and loss-of-function assays were performed to evaluate the functions of circKIAA1617 in ER-positive BC cells. Chromatin immunoprecipitation (ChIP) and luciferase assays verified the regulatory effects of estrogen on circKIAA1617 expression. RNA pulldown experiments, proteomic analyses, and RNA immunoprecipitation were conducted to identify the downstream targets of circKIAA1617.
resultsCircKIAA1617 expression was upregulated in ER-positive BC cells and tissues, indicating an unfavorable prognosis. In vitro and in vivo studies proved the circKIAA1617 increased the proliferation and stemness of ER-positive BC cells by inducing autophagy. Mechanistically, circKIAA1617 was activated by estrogen and cyclized by EIF4A3. Moreover, circKIAA1617 could act as a scaffold to enhance the interaction between the PGRMC1 and USP14 proteins, further increasing the stability of the PGRMC1 protein by decreasing its K48-linked polyubiquitination at lysine 105. In addition, autophagy activated by the circKIAA1617/USP14/PGRMC1 axis further modulated lipid metabolic reprogramming in ER-positive BC by increasing lipophagy, which accounted for the proliferation, stemness and autophagy of ER-positive BC.
conclusionsOur results revealed that circKIAA1617 promoted the proliferation and stemness of BC cells by regulating USP14/PGRMC1-mediated autophagy and lipid metabolic reprogramming and could serve as a potential diagnostic biomarker for ER-positive BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.